SynAct Pharma AB

OM:SYNACT Stock Report

Market Cap: SEK 462.5m

SynAct Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

OM:SYNACT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Mar 24BuySEK 98,325Thomas BoesenIndividual14,250SEK 6.90
21 Mar 24SellSEK 144,900Thomas BoesenIndividual21,000SEK 6.90

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of SYNACT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,425,19015.6%
Institutions6,870,76516.6%
General Public13,294,75732.2%
Private Companies14,705,75235.6%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.1%.

Top Shareholders

Top 20 shareholders own 68.69% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.8%
NBCD A/S
5,302,732SEK 59.4m33.8%no data
9.6%
Sanos Bioscience A/S
3,962,790SEK 44.4m0%no data
6.78%
Avanza Fonder AB
2,799,870SEK 31.4m47.6%0.03%
6.32%
Thomas Jonassen
2,610,032SEK 29.2m684%no data
5.53%
Thomas Ringberg
2,282,729SEK 25.6m1.32%no data
5.23%
TJ Biotech Invest ApS
2,161,225SEK 24.2m0%no data
4.11%
Nordnet AB (publ), Asset Management Arm
1,698,777SEK 19.0m0%0.24%
3.63%
Heights Capital Management, Inc.
1,500,000SEK 16.8m0%0.18%
3.63%
Ryan Quinn
1,500,000SEK 16.8m0%no data
3.46%
Quantass Invest Aps
1,428,558SEK 16.0m0%no data
2.81%
Goodwind Holding GmbH
1,161,777SEK 13.0m0%no data
1.89%
Handelsbanken Asset Management
781,198SEK 8.7m0%no data
1.67%
Bioinvest Sverige Ab
688,670SEK 7.7m0%no data
0.76%
SEB Investment Management AB
311,951SEK 3.5m0%no data
0.22%
FCG Fonder AB
91,386SEK 1.0m0%0.01%
0.089%
Skandia Fonder AB
36,871SEK 412.9k0%no data
0.045%
Thomas Boesen
18,604SEK 208.4k0%no data
0.033%
Jeppe Ovlesen
13,825SEK 154.9k0%no data
0.03%
Storebrand Fonder AB,
12,469SEK 139.6k0%no data
0.0026%
State Street Global Advisors, Inc.
1,067SEK 11.9k30.3%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 20:47
End of Day Share Price 2025/01/09 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SynAct Pharma AB is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrik LingDNB Markets
Carl RamaniusRedeye